Cargando…
BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
BACKGROUND: The effects of BRAF(non-V600E) and BRAF(V600E) on the outcomes and the molecular characteristics of adult glioma patients are unknown and need to be explored, although BRAF(V600E) has been extensively studied in pediatric glioma. METHODS: Co-occurring mutations and copy number alteration...
Autores principales: | Wang, Wei, Wang, Maode, Jiang, Haitao, Wang, Tuo, Da, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114535/ https://www.ncbi.nlm.nih.gov/pubmed/33980169 http://dx.doi.org/10.1186/s12883-021-02224-6 |
Ejemplares similares
-
BRAF
(AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF
(V600E)
por: Da, Rong, et al.
Publicado: (2021) -
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018) -
Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016) -
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013) -
LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)